$THC

BIERMAN JAMES L sold $1.2M of THC

BIERMAN JAMES L sold 5,000 shares of TENET HEALTHCARE CORP (THC) at $244.96 ($1.22M total) on 2026-07-27.

Original reporting
SEC EDGAR · BIERMAN JAMES L
Published Jul 29, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest fact is the specific sale size (5,000 shares), price ($244.96), and total proceeds ($1.2248M) reported in the Form 4.

02

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone does not provide new fundamentals or guidance.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), nor does it provide context on total compensation, prior sales cadence, or remaining holdings beyond the post-transaction figure.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-28 for a 2026-07-27 sale.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Tenet Healthcare director James L Bierman.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director James L Bierman filed a Form 4 selling 5,000 shares at $244.96 on 2026-07-27, totaling $1.2248M.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it is an open-market sale with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.

Market effects

No sector-level read-across provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-scheduled liquidity needs, so the signal may be weaker than headline sentiment suggests.

Key entities

  • TENET HEALTHCARE CORP

    Company whose director insider sale is disclosed on Form 4.

  • BIERMAN JAMES L

    Director who sold 5,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.